AbbVie Inc. (NYSE:ABBV) is one of the debt free halal stocks to buy. On March 3, at the TD Cowen 46th Annual Health Care Conference, AbbVie Inc. (NYSE:ABBV) affirmed its robust research and development pipeline, commercial strategies, and future growth plans.
RAJ CREATIONZS / shutterstock.com
The company reiterated that it is on course to achieve a high single-digit compound annual growth rate through 2029. The growth will be driven by a diversified pipeline as the company increasingly focuses on bolstering its immunology, oncology, and neuroscience, with promising assets like SKYRIZI and RINVOQ.
AbbVie is also exploring B-cell-depleting strategies and mRNA-based CAR-T therapies for rheumatologic diseases. It’s also leveraging its expertise in immunology and CNS to develop an obesity drug. Even as it continues developing its pipeline, it is launching tavapadone to target a $5 billion market opportunity in Parkinson’s disease.
The pipeline development and launch of new drugs come on the heels of AbbVie increasing its research and development expenditure, with over $8 billion already spent on business development over the past two years.
AbbVie Inc. is a global research-driven biopharmaceutical company focused on discovering, developing, and commercializing advanced therapies for complex, serious diseases. Key areas include immunology, oncology, neuroscience, eye care, and aesthetic medicine (via Allergan).
READ NEXT: 12 Best Consumer Goods Stocks Billionaires Are Quietly Buying and Goldman Sachs Penny Stocks: Top 12 Stock Picks.
